Can an oncolytic virus therapy challenge the standard of care in bladder cancer? CG Oncology has $120M to find out
CG Oncology is cashing in on its interim data update.
Tuesday morning, the Irvine, CA-based biotech announced that it raised $120 million — eclipsing the combined $87 million it’s brought in since its inception 12 years ago. The raise comes after CG posted updated data at SITC for its oncolytic virus candidate in combination with Keytruda for non-muscle invasive bladder cancer, or NMIBC, in patients who did not respond to standard Bacillus Calmette-Guérin (BCG) therapy.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,500+ biopharma pros reading Endpoints daily — and it's free.